Can-Fite BioPharma (CANF) Tops Q1 EPS by 63c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update
June 1, 2020 7:00 AM EDTCompany to host conference call at 8:30 a.m. ET today, June 1 Achieved efficacy and safety endpoints in Phase II NASH trial, with all cases of NASH significantly resolved after 12 weeks of treatment with 25 mg Namodenoson Pre-IND filed with FDA for clinical study of Piclidenoson in treatment of COVID-19 Interim results from Phase III Piclidenoson trial for psoriasis and rheumatoid arthritis expected Q4 2020
PETACH TIKVA, Israel--(BUSINESS... More
